{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:10:25Z","timestamp":1774008625609,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82304311"],"award-info":[{"award-number":["82304311"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81903460"],"award-info":[{"award-number":["81903460"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Sichuan Medical Association Program","award":["Q2024004"],"award-info":[{"award-number":["Q2024004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10495-025-02235-5","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:20:09Z","timestamp":1768036809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A selenium-containing selective estrogen receptor modulator to overcome drug resistance of chronic myeloid leukemia"],"prefix":"10.1007","volume":"31","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qulian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"3","key":"2235_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung HYA, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-a Cancer J Clin 74(3):229\u2013263","journal-title":"CA-a Cancer J Clin"},{"key":"2235_CR2","doi-asserted-by":"publisher","first-page":"101196","DOI":"10.1016\/j.blre.2024.101196","volume":"65","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liang ZJ, Gale RP, Liao HZ, Ma J, Gong TJ, Shao YQ, Liang Y (2024) Chronic myeloid leukaemia: biology and therapy. Blood Rev 65:101196","journal-title":"Blood Rev"},{"issue":"1","key":"2235_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.yapd.2023.04.002","volume":"70","author":"M Gotesman","year":"2023","unstructured":"Gotesman M, Raheel S, Panosyan EH (2023) Chronic myeloid leukemia in children and adolescents. Adv Pediatr 70(1):145\u2013155","journal-title":"Adv Pediatr"},{"issue":"1","key":"2235_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12032-021-01462-5","volume":"38","author":"P Singh","year":"2021","unstructured":"Singh P, Kumar V, Gupta SK, Kumari G, Verma M (2021) Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with tkis: a review. Med Oncol 38(1):10","journal-title":"Med Oncol"},{"issue":"11","key":"2235_CR5","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.3390\/cancers12113443","volume":"12","author":"M Mostazo","year":"2020","unstructured":"Mostazo M, Kurrle N, Casado M, Fuhrmann D, Alshamleh I, H\u00e4upl B, Mart\u00edn-Sanz P, Br\u00fcne B, Serve H, Schwalbe H, Schn\u00fctgen F, Marin S, Cascante M (2020) Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Cancers 12(11):3443","journal-title":"Cancers"},{"issue":"1","key":"2235_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-022-02298-1","volume":"41","author":"T Yang","year":"2022","unstructured":"Yang T, Sim K-Y, Ko G-H, Ahn J-S, Kim H-J, Park S-G (2022) FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-\u03baB signaling activation. J Exp Clin Cancer Res 41(1):82","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"2235_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim D-W, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Soria V, Coutre P, Mahon F-X, Janssen J, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F (2023) Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior tkis: 4-year phase 1 safety and efficacy results. Leukemia 37(5):1048\u20131059","journal-title":"Leukemia"},{"issue":"7\u20138","key":"2235_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000524284","volume":"45","author":"S Saussele","year":"2022","unstructured":"Saussele S, Kohlbrenner K, Vogelmann T, Schubert T (2022) Incidence, Prevalence, and real-world treatment patterns in chronic myeloid leukemia: results from a population-representative German claims data analysis. Oncol Res Treat 45(7\u20138):400\u2013406","journal-title":"Oncol Res Treat"},{"issue":"1","key":"2235_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan OY, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K (2024) Chronic myeloid leukemia, version 2. J Nat Compr Cancer Netw 22(1):43\u201369","journal-title":"J Nat Compr Cancer Netw"},{"issue":"11","key":"2235_CR10","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Polakova KM, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S (2023) European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia 37(11):2150\u20132167","journal-title":"Leukemia"},{"issue":"2","key":"2235_CR11","doi-asserted-by":"publisher","first-page":"100187","DOI":"10.1016\/j.mcpro.2021.100187","volume":"21","author":"W Liu","year":"2022","unstructured":"Liu W, Sun YT, Ge WG, Zhang FF, Gan L, Zhu Y, Guo TN, Liu K (2022) X., DIA-Based proteomics identifies IDH2 as a targetable regulator of acquired drug resistance in chronic myeloid leukemia. Mol Cell Proteom 21(2):100187","journal-title":"Mol Cell Proteom"},{"issue":"6","key":"2235_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.bbmt.2020.02.006","volume":"26","author":"S Schmidt","year":"2020","unstructured":"Schmidt S, Liu Y, Hu Z-H, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ort\u00ed G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, JHsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Chakrabarty JH, Saber W (2020) The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era. Biol Blood Marrow Transpl 26(6):1137\u20131143","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2235_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.stem.2020.04.005","volume":"27","author":"K Rothe","year":"2020","unstructured":"Rothe K, Babaian A, Nakamichi N, Chen M, Chafe SC, Watanabe A, Forrest DL, Mager DL, Eaves CJ, Dedhar S, Jiang X (2020) Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors. Cell Stem Cell 27(1):110\u2013124","journal-title":"Cell Stem Cell"},{"issue":"12","key":"2235_CR14","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1007\/s00277-024-06045-8","volume":"103","author":"BJ Lee","year":"2024","unstructured":"Lee BJ, Griffin SP, Doh J, Ciurea SO, Jeyakumar D, Kongtim P, Naqvi K (2024) Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience. Ann Hematol 103(12):5395\u20135403","journal-title":"Ann Hematol"},{"issue":"2","key":"2235_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/aps.2017.100","volume":"39","author":"L Li","year":"2018","unstructured":"Li L, You L-S, Mao L-P, Jin S-H, Chen X-H, Qian W-B (2018) Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro. Acta Pharmacol Sin 39(2):251\u2013260","journal-title":"Acta Pharmacol Sin"},{"issue":"20","key":"2235_CR16","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.2174\/0109298673267738231129104216","volume":"32","author":"Y Liu","year":"2025","unstructured":"Liu Y, Yang Z, Zhang Q, Hai P, Zheng Y, Zhang J, Pan X (2025) Recent advances in signaling pathways and kinase inhibitors for leukemia chemotherapy. Curr Med Chem 32(20):4000\u20134032","journal-title":"Curr Med Chem"},{"issue":"1","key":"2235_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-021-01106-1","volume":"14","author":"K Saxena","year":"2021","unstructured":"Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian P, Short NJ (2021) Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 14(1):94","journal-title":"J Hematol Oncol"},{"issue":"15","key":"2235_CR18","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/1873-3468.13480","volume":"593","author":"F Zhang","year":"2019","unstructured":"Zhang F, Ni H, Li X, Liu H, Xi T, Zheng L (2019) LncRNA FENDRR attenuates adriamycin resistance via suppressing MDR1 expression through sponging HuR and miR-184 in chronic myelogenous leukaemia cells. FEBS Lett 593(15):1993\u20132007","journal-title":"FEBS Lett"},{"key":"2235_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cbi.2018.04.012","volume":"288","author":"J Pan","year":"2018","unstructured":"Pan J, Miao D, Chen L (2018) Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562\/ADM cells by suppressing MDR1 gene\/P-glycoprotein expression. Chem Biol Interact 288:32\u201337","journal-title":"Chem Biol Interact"},{"issue":"4","key":"2235_CR20","first-page":"1910","volume":"39","author":"X Ma","year":"2018","unstructured":"Ma X, Zhou X, Qu H, Ma Y, Yue Z, Shang W, Wang P, Xie S, Li Y, Sun Y (2018) TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK\/STAT3 signaling pathway in human chronic myelogenous leukemia K562\/ADM cells. Oncol Rep 39(4):1910\u20131918","journal-title":"Oncol Rep"},{"issue":"1\u201302","key":"2235_CR21","first-page":"19","volume":"91","author":"C Stutz","year":"2025","unstructured":"Stutz C, Font\u00e3o A, Silva G, Seito L, Perdomo RT, Sampaio A (2025) Betulinic acid acts in synergism with imatinib mesylate, triggering apoptosis in MDR leukemia cells. Planta Med 91(1\u201302):19\u201328","journal-title":"Planta Med"},{"key":"2235_CR22","doi-asserted-by":"publisher","first-page":"1265199","DOI":"10.3389\/fbioe.2023.1265199","volume":"11","author":"P Zhao","year":"2023","unstructured":"Zhao P, Zhong Y, Pan P, Zhang S, Tian Y, Zhang J, Yi G, Zhao Z, Wu T (2023) DNA self-assembly nanoflower reverse P-glycoprotein mediated drug resistance in chronic myelogenous leukemia therapy. Front Bioeng Biotechnol 11:1265199","journal-title":"Front Bioeng Biotechnol"},{"key":"2235_CR23","doi-asserted-by":"publisher","first-page":"147848","DOI":"10.1016\/j.gene.2023.147848","volume":"892","author":"AP Lettnin","year":"2024","unstructured":"Lettnin AP, Wagner EF, Salgado M, Ca\u00f1edo A, Rumjanek VM, Trindade GS (2024) Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia. Gene 892:147848","journal-title":"Gene"},{"issue":"4","key":"2235_CR24","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1159\/000495650","volume":"51","author":"W Liu","year":"2018","unstructured":"Liu W, Meng Q, Sun Y, Wang C, Huo X, Liu Z, Sun P, Sun H, Ma X, Liu K (2018) Targeting P-Glycoprotein: nelfinavir reverses adriamycin resistance in K562\/ADR cells. Cell Physiol Biochem 51(4):1616\u20131631","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"2235_CR25","doi-asserted-by":"publisher","first-page":"e23374","DOI":"10.1002\/jcla.23374","volume":"34","author":"M Ammar","year":"2020","unstructured":"Ammar M, Louati N, Frikha I, Medhaffar M, Ghozzi H, Elloumi M, Menif H, Zeghal K, Mahmoud LB (2020) Overexpression of P-glycoprotein and resistance to imatinib in chronic myeloid leukemia patients. J Clin Lab Anal 34(9):e23374","journal-title":"J Clin Lab Anal"},{"issue":"17","key":"2235_CR26","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.3390\/jcm11174954","volume":"11","author":"EK Al-Amleh","year":"2022","unstructured":"Al-Amleh EK, Al-Sanabra OM, Alqaisi KM, Alqaraleh M, Al-Nahal J, Hamadneh L, Malki MI, Alhmoud JF (2022) Investigation of the effect of imatinib and hydroxyurea combination therapy on hematological parameters and gene expression in chronic myeloid leukemia (CML) patients. J Clin Med 11(17):4954","journal-title":"J Clin Med"},{"issue":"12","key":"2235_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s12032-022-01821-w","volume":"39","author":"Y Liang","year":"2022","unstructured":"Liang Y, Qin Y, Jiang G, Feng W, Yuan Y (2022) Targeting MDC1 promotes apoptosis and sensitizes imatinib resistance in CML cells by mainly disrupting non-homologous end-joining repair. Med Oncol 39(12):226","journal-title":"Med Oncol"},{"issue":"1","key":"2235_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13046-019-1502-7","volume":"39","author":"Z-Y Nie","year":"2020","unstructured":"Nie Z-Y, Yao M, Yang Z, Yang L, Liu X-J, Yu J, Ma Y, Zhang N, Zhang X-Y, Liu M-H, Jiang L-L, Luo J-M (2020) De-regulated STAT5A\/miR-202-5p\/USP15\/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to imatinib resistance. J Exp Clin Cancer Res 39(1):17","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"2235_CR29","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1080\/15548627.2023.2200554","volume":"19","author":"Q Xue","year":"2023","unstructured":"Xue Q, Kang R, Klionsky DJ, Tang DL, Liu JB, Chen X (2023) Copper metabolism in cell death and autophagy. Autophagy 19(8):2175\u20132195","journal-title":"Autophagy"},{"key":"2235_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13046-017-0512-6","volume":"36","author":"ZY Lu","year":"2017","unstructured":"Lu ZY, Xu N, He BL, Pan CY, Lan YQ, Zhou HS, Liu XL (2017) Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia. J Exp Clin Cancer Res 36:43","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2235_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/biology12020307","volume":"12","author":"MH Yang","year":"2023","unstructured":"Yang MH, Ha IJ, Lee SG, Lee JH, Um JY, Sethi G, Ahn KS (2023) Brassinin induces apoptosis, autophagy, and paraptosis via MAPK signaling pathway activation in chronic myelogenous leukemia cells. Biology 12(2):307","journal-title":"Biology"},{"issue":"6","key":"2235_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.stem.2014.11.002","volume":"15","author":"A S\u00e1nchez-Aguilera","year":"2014","unstructured":"S\u00e1nchez-Aguilera A, Arranz L, Mart\u00edn-P\u00e9rez D, Garc\u00eda-Garc\u00eda A, Stavropoulou V, Kubovcakova L, Isern J, Mart\u00edn-Salamanca S, Langa X, Skoda RC, Schwaller J, M\u00e9ndez-Ferrer S (2014) Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell 15(6):791\u2013804","journal-title":"Cell Stem Cell"},{"issue":"13","key":"2235_CR33","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1182\/blood-2013-07-517292","volume":"123","author":"K Yakimchuk","year":"2014","unstructured":"Yakimchuk K, Hasni MS, Guan JY, Chao MP, Sander B, Okret S (2014) Inhibition of lymphoma vascularization and dissemination by estrogen receptor \u03b2 agonists. Blood 123(13):2054\u20132061","journal-title":"Blood"},{"issue":"7","key":"2235_CR34","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/cbin.12017","volume":"47","author":"M Mishra","year":"2023","unstructured":"Mishra M, Singh AK, Thacker G, Upadhyay V, Sanyal S, Trivedi AK (2023) Ormeloxifene, a nonsteroidal antifertility drug promotes megakaryocyte differentiation in leukemia cell line K562. Cell Biol Int 47(7):1247\u20131258","journal-title":"Cell Biol Int"},{"key":"2235_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu PD (2022) Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Sem Cancer Biol 85:69\u201394","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"2235_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22(1):138","journal-title":"Mol Cancer"},{"issue":"11","key":"2235_CR37","doi-asserted-by":"publisher","first-page":"7993","DOI":"10.1021\/acs.jmedchem.2c00525","volume":"65","author":"XP Deng","year":"2022","unstructured":"Deng XP, Xie BH, Li QZ, Xiao Y, Hu ZY, Deng XF, Fang PP, Dong CN, Zhou HB, Huang J (2022) Discovery of novel bicyclic phenylselenyl-containing hybrids: an orally bioavailable, potential, and multiacting class of estrogen receptor modulators against endocrine-resistant breast cancer. J Med Chem 65(11):7993\u20138010","journal-title":"J Med Chem"},{"key":"2235_CR38","doi-asserted-by":"publisher","first-page":"113621","DOI":"10.1016\/j.ejmech.2021.113621","volume":"223","author":"HY Chuai","year":"2021","unstructured":"Chuai HY, Zhang SQ, Bai HR, Li JY, Wang Y, Sun JJ, Wen EG, Zhang JY, Xin MH (2021) Small molecule selenium-containing compounds: recent development and therapeutic applications. Eur J Med Chem 223:113621","journal-title":"Eur J Med Chem"},{"issue":"3","key":"2235_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/cmdc.201600593","volume":"12","author":"SL Zhang","year":"2017","unstructured":"Zhang SL, Wang ZY, Hu ZY, Li CH, Tang C, Carlson KE, Luo JJ, Dong C, Katzenellenbogen JA, Huang J, Zhou HB (2017) Selenophenes: introducing a new element into the core of non-steroidal estrogen receptor ligands. ChemMedChem 12(3):235\u2013249","journal-title":"ChemMedChem"},{"issue":"1","key":"2235_CR40","doi-asserted-by":"publisher","first-page":"e1009728","DOI":"10.1080\/23723556.2015.1009728","volume":"3","author":"A Sanchez-Aguilera","year":"2016","unstructured":"Sanchez-Aguilera A, Mendez-Ferrer S (2016) Regulation of hematopoietic progenitors by estrogens as a basis for new antileukemic strategies. Mol Cell Oncol 3(1):e1009728","journal-title":"Mol Cell Oncol"},{"issue":"2","key":"2235_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41401-019-0270-4","volume":"41","author":"X Liu","year":"2020","unstructured":"Liu X, Hu P, Li H, Yu XX, Wang XY, Qing YJ, Wang ZY, Wang HZ, Zhu MY, Guo QL, Hui H (2020) LW-213, a newly synthesized flavonoid, induces G2\/M phase arrest and apoptosis in chronic myeloid leukemia. Acta Pharmacol Sin 41(2):249\u2013259","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"2235_CR42","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/cells10102509","volume":"10","author":"R Sugiura","year":"2021","unstructured":"Sugiura R, Satoh R, Takasaki T (2021) A double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells 10(10):2509","journal-title":"Cells"},{"issue":"12","key":"2235_CR43","doi-asserted-by":"publisher","first-page":"B078","DOI":"10.1158\/1535-7163.TARG-19-B078","volume":"18","author":"AB Bhatt","year":"2019","unstructured":"Bhatt AB, Wright TD, Patel S, Chakrabarty S, Barnes V, Burow M, Burow M, Flaherty PT, Cavanaugh J (2019) Inhibition of the MAPK pathways enhances the sensitivity of triple negative breast cancer cells to chemotherapeutic drugs. Mol Cancer Ther 18(12):B078","journal-title":"Mol Cancer Ther"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02235-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02235-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02235-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:02:05Z","timestamp":1774000925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02235-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02235-5","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures and animal experiments were approved by the Animal Ethnical Committee of Southwest Medical University (project number: 20220221-013) and conducted according to the Guide for the Care and Use of Laboratory Animals (8th edn) published by NIH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}